Claims
- 1. An isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and complements thereof.
- 2. The isolated nucleic acid molecule according to claim 1, wherein said nucleic acid sequence is SEQ ID NO: 1.
- 3. The isolated nucleic acid molecule according to claim 1, wherein said nucleic acid sequence is SEQ ID NO: 2.
- 4. The isolated nucleic acid molecule according to claim 1, wherein said nucleic acid sequence is SEQ ID NO: 3.
- 5. An isolated nucleic acid molecule comprising a nucleic acid sequence that is at least 30 consecutive nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and complements thereof.
- 6. The isolated nucleic acid molecule according to claim 5, wherein said nucleic acid sequence is at least 50 consecutive nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and complements thereof.
- 7. The isolated nucleic acid molecule according to claim 6, wherein said nucleic acid sequence is at least 75 consecutive nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and complements thereof.
- 8. The isolated nucleic acid molecule according to claim 7, wherein said nucleic acid sequence is at least 100 consecutive nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and complements thereof.
- 9. The isolated nucleic acid molecule according to claim 8, wherein said nucleic acid sequence is at least 150 consecutive nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and complements thereof.
- 10. The isolated nucleic acid molecule according to claim 9, wherein said nucleic acid sequence is at least 200 consecutive nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and complements thereof.
- 11. The isolated nucleic acid molecule according to claim 10, wherein said nucleic acid sequence is at least 250 consecutive nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and complements thereof.
- 12. A vector comprising a nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and complements thereof operably linked to polypeptide encoding nucleic acid sequence.
- 13. A vector comprising a nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and complements thereof operably linked to a heterologous nucleic acid sequence in manner where the complement of said heterologous nucleic acid sequence is expressed.
- 14. A host cell having a heterologous nucleic acid molecule that comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and complements thereof.
- 15. A host cell having a heterologous nucleic acid molecule that comprises a nucleic acid sequence that is at least 30 consecutive nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and complements thereof.
- 16. A plant having a heterologous nucleic acid molecule that comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and complements thereof.
- 17. A plant having a heterologous nucleic acid molecule that comprises a nucleic acid sequence that is at least 30 consecutive nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and complements thereof.
- 18. A method of screening for compounds capable of effecting the level of gamma-tocopherol methyltransferase expression comprising:
(a) providing a cell with a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and complements thereof operably linked to a heterologous nucleic acid sequence in manner where the complement of said heterologous nucleic acid sequence is expressed; (b) providing a test compound to said cell; and (c) determining the level of said complement of said heterologous nucleic acid sequence or a polypeptide encoded by said heterologous nucleic acid sequence.
- 19. A method according to claim 18, wherein said heterologous sequence encodes a marker polypeptide.
- 20. A method according to claim 19, where said marker polypeptide is selected from the group consisting of GFP, GUS, LUX, antibiotic markers, and herbicide tolerance markers.
- 21. A method of determining the presence of a nucleic acid sequence of at least 200 consecutive nucleotides in a sample comprising:
(a) contacting the sample with a nucleic acid probe that hybridizes to a nucleic acid sequence having the sequence of SEQ ID NO: 1; and (b) determining whether the nucleic acid probe hybridizes to a nucleic acid molecule in said sample.
Parent Case Info
[0001] This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Patent Application Serial No. 60/267,330, filed Feb. 8, 2001, which application is herein incorporated by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60267330 |
Feb 2001 |
US |